• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

俄罗斯EQ-5D-3L量表的估值

Valuation of the EQ-5D-3L in Russia.

作者信息

Omelyanovskiy Vitaly, Musina Nuriya, Ratushnyak Svetlana, Bezdenezhnykh Tatiana, Fediaeva Vlada, Roudijk Bram, Purba Fredrick Dermawan

机构信息

Center of Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation, Moscow, Russia.

Financial Research Institute at the Ministry of Finances of the Russian Federation, Moscow, Russia.

出版信息

Qual Life Res. 2021 Jul;30(7):1997-2007. doi: 10.1007/s11136-021-02804-6. Epub 2021 Mar 13.

DOI:10.1007/s11136-021-02804-6
PMID:33713323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8233249/
Abstract

PURPOSE

The most widely used generic questionnaire to estimate the quality of life for yielding quality-adjusted life years in economic evaluations is EQ-5D. Country-specific population value sets are required to use EQ-5D in economic evaluations. The aim of this study was to establish an EQ-5D-3L value set for Russia.

METHODS

A representative sample aged 18+ years was recruited from the Russia`s general population. Computer-assisted face-to-face interviews were conducted based on the standardized valuation protocol using EQ-Portable Valuation Technology. Population preferences were elicited utilizing both composite time trade-off (cTTO) and discrete choice experiment (DCE) techniques. To estimate the value set, a hybrid regression model combining cTTO and DCE data was used.

RESULTS

A total of 300 respondents who successfully completed the interview were included in the primary analysis. 120 (40.0%) respondents reported no health problems of any dimension, and 56 (18.7%) reported moderate health problems in one dimension of the EQ-5D-3L. Median self-rated health using EQ-VAS was 80 with IQR 70-90. Comparing cTTO and DCE-predicted values for 243 health states resulted in a similar pattern. This supports the use of hybrid models. The predicted value based on the preferred model for the worst health state "33333" was -0.503. Mobility dimension had the most significant impact on the utility decrement, and anxiety/depression had the lowest decrement.

CONCLUSION

Determining a Russian national value set may be considered the first step towards promoting cost-utility analysis use to increase comparability among studies and improve the transferability of healthcare decision-making in Russia.

摘要

目的

在经济评估中用于估算产生质量调整生命年的生活质量的最广泛使用的通用问卷是EQ-5D。在经济评估中使用EQ-5D需要特定国家的人群价值集。本研究的目的是为俄罗斯建立一个EQ-5D-3L价值集。

方法

从俄罗斯普通人群中招募了年龄在18岁及以上的代表性样本。基于标准化评估协议,使用EQ便携式评估技术进行计算机辅助面对面访谈。利用复合时间权衡(cTTO)和离散选择实验(DCE)技术来获取人群偏好。为了估计价值集,使用了结合cTTO和DCE数据的混合回归模型。

结果

共有300名成功完成访谈的受访者被纳入初步分析。120名(40.0%)受访者报告在任何维度上都没有健康问题,56名(18.7%)受访者报告在EQ-5D-3L的一个维度上存在中度健康问题。使用EQ-VAS自评健康的中位数为80,四分位间距为70-90。比较243种健康状态的cTTO和DCE预测值,结果呈现出相似的模式。这支持了混合模型的使用。基于首选模型对最差健康状态“33333”的预测值为-0.503。行动能力维度对效用降低的影响最大,焦虑/抑郁维度的降低最小。

结论

确定俄罗斯国家价值集可被视为朝着促进成本效用分析的应用迈出的第一步,以提高研究之间的可比性,并改善俄罗斯医疗保健决策的可转移性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/4dfdba18a465/11136_2021_2804_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/3ed8f8aa5d57/11136_2021_2804_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/3c66480eef79/11136_2021_2804_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/02288c8a9abe/11136_2021_2804_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/3fb1926f1efe/11136_2021_2804_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/4dfdba18a465/11136_2021_2804_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/3ed8f8aa5d57/11136_2021_2804_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/3c66480eef79/11136_2021_2804_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/02288c8a9abe/11136_2021_2804_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/3fb1926f1efe/11136_2021_2804_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f47d/8233249/4dfdba18a465/11136_2021_2804_Fig5_HTML.jpg

相似文献

1
Valuation of the EQ-5D-3L in Russia.俄罗斯EQ-5D-3L量表的估值
Qual Life Res. 2021 Jul;30(7):1997-2007. doi: 10.1007/s11136-021-02804-6. Epub 2021 Mar 13.
2
A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.一种用于获取健康状态偏好的混合建模方法:葡萄牙 EQ-5D-5L 值集。
Qual Life Res. 2019 Dec;28(12):3163-3175. doi: 10.1007/s11136-019-02226-5. Epub 2019 Jun 14.
3
Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.采用混合方法评估健康相关生命质量:适用于 EQ-5D-3L 的突尼斯价值体系。
Qual Life Res. 2021 May;30(5):1445-1455. doi: 10.1007/s11136-020-02730-z. Epub 2021 Jan 14.
4
Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.平行评估:EQ-5D-3L 和 EQ-5D-5L 社会价值集的直接比较。
Med Decis Making. 2018 Nov;38(8):968-982. doi: 10.1177/0272989X18802797.
5
United States Valuation of EQ-5D-5L Health States Using an International Protocol.美国使用国际协议对 EQ-5D-5L 健康状态进行评估。
Value Health. 2019 Aug;22(8):931-941. doi: 10.1016/j.jval.2019.02.009. Epub 2019 May 25.
6
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.基于离散选择实验(DCE)到时间权衡(TTO)值的映射来估计印度尼西亚的 EQ-5D-Y-3L 值集。
Pharmacoeconomics. 2022 Dec;40(Suppl 2):157-167. doi: 10.1007/s40273-022-01210-1. Epub 2022 Nov 9.
7
Value Set for the EQ-5D-Y-3L in Hungary.匈牙利的 EQ-5D-Y-3L 量表值。
Pharmacoeconomics. 2022 Dec;40(Suppl 2):205-215. doi: 10.1007/s40273-022-01190-2. Epub 2022 Sep 20.
8
The EQ-5D-3L Valuation Study in Pakistan.巴基斯坦的EQ-5D-3L估值研究。
Pharmacoecon Open. 2023 Nov;7(6):963-974. doi: 10.1007/s41669-023-00437-8. Epub 2023 Sep 13.
9
Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.波兰的 EQ-5D-5L 健康状态估值:中欧和东欧的首次基于 EQ-VT 的研究。
Pharmacoeconomics. 2019 Sep;37(9):1165-1176. doi: 10.1007/s40273-019-00811-7.
10
Dutch Tariff for the Five-Level Version of EQ-5D.EQ-5D五级版本的荷兰关税。
Value Health. 2016 Jun;19(4):343-52. doi: 10.1016/j.jval.2016.01.003. Epub 2016 Mar 30.

引用本文的文献

1
Mapping EQ-5D-5L Score From SGRQ in Patients with Asthma and/or COPD in NOVELTY.在“新颖性”研究中,将哮喘和/或慢性阻塞性肺疾病患者的圣乔治呼吸问卷(SGRQ)评分映射到欧洲五维度健康量表-5级(EQ-5D-5L)评分。
Pragmat Obs Res. 2025 Jun 4;16:135-145. doi: 10.2147/POR.S508814. eCollection 2025.
2
Valuation of the EQ-5D-3L in Jordan.约旦EQ-5D-3L量表的估值
Eur J Health Econ. 2025 Apr;26(3):487-501. doi: 10.1007/s10198-024-01712-z. Epub 2024 Sep 3.
3
Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR.

本文引用的文献

1
Population norms of health-related quality of life in Moscow, Russia: the EQ-5D-5L-based survey.俄罗斯莫斯科健康相关生活质量的人口常模:基于 EQ-5D-5L 的调查。
Qual Life Res. 2021 Mar;30(3):831-840. doi: 10.1007/s11136-020-02705-0. Epub 2020 Nov 25.
2
Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.哪些多属性效用仪器推荐用于成本效用分析?国家卫生技术评估(HTA)指南的回顾。
Eur J Health Econ. 2020 Nov;21(8):1245-1257. doi: 10.1007/s10198-020-01195-8. Epub 2020 Jun 8.
3
Valuing Health States in Russia: A First Feasibility Study.
在活动性类风湿关节炎患者中联合甲氨蝶呤使用利维利珠单抗的疗效和安全性:III 期随机双盲安慰剂对照试验 SOLAR 的 56 周结果。
Dokl Biochem Biophys. 2024 Oct;518(1):403-416. doi: 10.1134/S1607672924701072. Epub 2024 Aug 28.
4
The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol.百慕大的EQ-5D-3L评估研究:采用在线EQ-VT方案。
Eur J Health Econ. 2025 Mar;26(2):275-297. doi: 10.1007/s10198-024-01701-2. Epub 2024 Jul 9.
5
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.EORTC QLU-C10D 是一种在荷兰具有成本效用和卫生技术评估有效性的癌症特异性偏好测量工具。
Eur J Health Econ. 2024 Dec;25(9):1539-1555. doi: 10.1007/s10198-024-01670-6. Epub 2024 Mar 14.
6
The EQ-5D-3L Valuation Study in Pakistan.巴基斯坦的EQ-5D-3L估值研究。
Pharmacoecon Open. 2023 Nov;7(6):963-974. doi: 10.1007/s41669-023-00437-8. Epub 2023 Sep 13.
7
Eliciting a value set for the Swedish Capability-Adjusted Life Years instrument (CALY-SWE).为瑞典能力调整生命年量表(CALY-SWE)制定价值观体系。
Qual Life Res. 2024 Jan;33(1):59-72. doi: 10.1007/s11136-023-03507-w. Epub 2023 Sep 11.
8
Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends.离散选择实验在健康状态估值中的应用:进展与新趋势的系统综述。
Appl Health Econ Health Policy. 2023 May;21(3):405-418. doi: 10.1007/s40258-023-00794-9. Epub 2023 Mar 30.
9
Health-related quality of life assessed by EQ-5D-5L and its determinants among rural adults: result from the Henan rural cohort study.农村成年人的 EQ-5D-5L 评估的健康相关生活质量及其决定因素:来自河南农村队列研究的结果。
Eur J Health Econ. 2024 Feb;25(1):21-30. doi: 10.1007/s10198-023-01565-y. Epub 2023 Jan 30.
10
First population norms for the EQ-5D-3L in the Russian Federation.俄罗斯联邦的 EQ-5D-3L 的首个群体常模。
PLoS One. 2022 Mar 29;17(3):e0263816. doi: 10.1371/journal.pone.0263816. eCollection 2022.
俄罗斯的健康状态评估:首次可行性研究
Value Health Reg Issues. 2019 Sep;19:75-80. doi: 10.1016/j.vhri.2019.01.005. Epub 2019 Jun 7.
4
Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.概述、更新以及从国际 EQ-5D-5L 估值工作中吸取的经验教训:EQ-5D-5L 估值议定书第 2 版。
Value Health. 2019 Jan;22(1):23-30. doi: 10.1016/j.jval.2018.05.010. Epub 2019 Jan 2.
5
Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey.基于全国代表性中国人群调查的 EQ-5D-3L 的时间权衡值集。
Value Health. 2018 Nov;21(11):1330-1337. doi: 10.1016/j.jval.2018.04.1370. Epub 2018 May 18.
6
Selecting Health States for EQ-5D-3L Valuation Studies: Statistical Considerations Matter.选择 EQ-5D-3L 估值研究中的健康状态:统计考虑至关重要。
Value Health. 2018 Apr;21(4):456-461. doi: 10.1016/j.jval.2017.09.001. Epub 2017 Oct 18.
7
Quality Control Process for EQ-5D-5L Valuation Studies.EQ-5D-5L 估值研究的质量控制流程
Value Health. 2017 Mar;20(3):466-473. doi: 10.1016/j.jval.2016.10.012. Epub 2016 Dec 22.
8
Response-Scale Heterogeneity in the EQ-5D.EQ-5D中的反应量表异质性
Health Econ. 2017 Mar;26(3):387-394. doi: 10.1002/hec.3313. Epub 2016 Jan 12.
9
Valuing EQ-5D health states for Sri Lanka.评估斯里兰卡的EQ-5D健康状态。
Qual Life Res. 2015 Jul;24(7):1785-93. doi: 10.1007/s11136-014-0906-2. Epub 2014 Dec 28.
10
Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach.使用混合方法对EQ-5D-5L健康状态进行估值和建模。
Med Care. 2017 Jul;55(7):e51-e58. doi: 10.1097/MLR.0000000000000283.